Safety of Arthritis Drugs, Day 1, Part 2
Physicians and others spoke at the meeting to assess the safety records of arthritis drugs. Among the topics they addressed were the mechanisms for the deployment of the medicine, risk factors calculated in initial tests, and the degree of usage of the class of drugs among the general population. They also answered questions from Food and Drug Administration officials.
A joint meeting of the Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees held a forum on the … read more
A joint meeting of the Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees held a forum on the safety of “COX-2” inhibitors. The function of the advisory committee was to provide advice and recommendations to the FDA on regulatory issues.
Physicians and others spoke at the meeting to assess the safety records of arthritis drugs. Among the topics they addressed were the mechanisms for the deployment of the medicine, risk factors calculated in initial tests, and the degree of usage of the class of drugs among the general population. They also answered questions from Food and Drug Administration officials. close
People in this video
More PeopleHosting Organization
More Videos From
Safety of Arthritis Drugs, Day 1,
More VideosRelated Video
-
Safety of Arthritis Drugs, Day 2, Part 1
Physicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drug Arcoxia and …
-
Open Phones
Telephone lines were open for viewer comments on the question, “Should painkiller Celebrex be pulled from the market?”
-
Food and Drug Safety
Food and Drug Administration Acting Commissioner Lester Crawford talked about consumer safety, regulatory practices at t…
-
Food and Drug Administration Issues
The Food and Drug Administration’s Acting Commissioner Lester Crawford talked about the Food and Drug Administration’s e…